John Hubbard of Bioclinica Elected 2017 ACRO Chairman, Medidata Joins Member Companies

Posted by January 30, 2017 10:29 am

Contact: John Lewis

202.464.9340

jlewis@acrohealth.org

John Hubbard of Bioclinica Elected 2017 ACRO Chairman

Medidata Joins Member Companies

January 30, 2017 – WASHINGTON, DC – The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected John Hubbard, Ph.D., President and CEO of Bioclinica, as 2017 Chairman and John Ratliff, CEO of Covance Drug Development, as Vice Chairman. Dr. Hubbard succeeds PPD Chairman and CEO David Simmons as Chair, and Mr. Simmons will remain active on the board.

Prior to becoming Bioclinica’s CEO in January 2015, Dr. Hubbard was Senior Vice President and Worldwide Head of Development Operations for Pfizer and prior to this was Group President of ICON plc’s Global Clinical Research Services Division. He has extensive experience in nearly all facets of biopharmaceutical research and development and has led several drug development teams to successful approval and commercialization of new chemical entities. Dr. Hubbard received a bachelor’s degree from the University of Santa Clara, a doctorate from the University of Tennessee, and was a National Institutes of Health postdoctoral fellow in Cardiovascular and Clinical Pharmacology at the University of Texas Health Sciences Center.

“I look forward to leading ACRO as the unified voice of the CRO industry at this time of tremendous change and opportunity,” said Dr. Hubbard. “I especially want to welcome Medidata into our growing and increasingly diverse membership and my friend Glen de Vries to the ACRO Board.”

ACRO’s successes in 2016 included significant input into the 21st Century Cures Act, expanded engagement across Europe and continued productive interaction with TransCelerate Biopharma Inc. through ACRO’s CRO Forum.

ACRO also elected as officers: Maria Kraus, Executive Vice President of Corporate Development and Strategy at Bioclinica, as Treasurer and Chris Gegelys, General Counsel at Covance Drug Development, as Secretary.

About ACRO
The Association of Clinical Research Organizations (ACRO) represents companies that provide a variety of specialized services that support the development of new pharmaceuticals, biologics, and medical devices. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ more than 130,000 professionals worldwide and conduct research in more than 100 countries. For more information, please visit www.acrohealth.org. Twitter @acrohealth. YouTube @ACROHealthChannel. Facebook. LinkedIn.